Results for tag: "Proliferative Diabetic Retinopathy"

Proliferative diabetic retinopathy (PDR) is an advanced stage of diabetic retinopathy, a complication of diabetes characterized by changes in the blood vessels of the retina. In the optical context, PDR management focuses on detecting and treating the proliferative changes that can lead to severe vision loss and blindness if left unaddressed. The use of optical coherence tomography (OCT), fluorescein angiography (FA) and fundus photography are essential diagnostic tools that help eye care professionals assess the severity of retinopathy and monitor its progression. Advanced optical technologies enable early diagnosis and continued monitoring, which is critical for timely intervention. Treatment for PDR typically includes panretinal photocoagulation (PRP) using laser therapy, which helps reduce the risk of severe vision loss by destroying areas of the retina receiving poor blood supply. Vitrectomy surgery might be necessary for advanced cases involving retinal detachment or vitreous hemorrhage. The advent of anti-VEGF (vascular endothelial growth factor) injections has offered an alternative or adjunctive therapeutic option to mitigate the neovascularization characteristic of PDR. Companies in the PDR market include pharmaceutical firms that produce anti-VEGF drugs like Genentech (Roche), Regeneron, and Novartis. Device manufacturers that produce OCT machines and laser equipment, such as Carl Zeiss Meditec, Topcon, and Canon, also play a significant role. Furthermore, companies specializing in diagnostic imaging software Show Less Read more